In:
Frontiers in Immunology, Frontiers Media SA, Vol. 13 ( 2022-10-21)
Abstract:
Coronavac is a widely used SARS-CoV-2 inactivated vaccine, but its long-term immune response assessment is still lacking. We evaluated SARS-CoV-2-specific immune responses, including T cell activation markers, antigen-specific cytokine production and antibody response following vaccination in 53 adult and elderly individuals participating in a phase 3 clinical trial. Activated follicular helper T (Tfh), non-Tfh and memory CD4 + T cells were detected in almost all subjects early after the first vaccine dose. Activated memory CD4 + T cells were predominantly of central and effector memory T cell phenotypes and were sustained for at least 6 months. We also detected a balanced Th1-, Th2- and Th17/Th22-type cytokine production that was associated with response over time, together with particular cytokine profile linked to poor responses in older vaccinees. SARS-CoV-2-specific IgG levels peaked 14 days after the second dose and were mostly stable over one year. CoronaVac was able to induce a potent and durable antiviral antigen-specific cellular response and the cytokine profiles related to the response over time and impacted by the senescence were defined.
Type of Medium:
Online Resource
ISSN:
1664-3224
DOI:
10.3389/fimmu.2022.1032411
DOI:
10.3389/fimmu.2022.1032411.s001
DOI:
10.3389/fimmu.2022.1032411.s002
DOI:
10.3389/fimmu.2022.1032411.s003
DOI:
10.3389/fimmu.2022.1032411.s004
DOI:
10.3389/fimmu.2022.1032411.s005
DOI:
10.3389/fimmu.2022.1032411.s006
DOI:
10.3389/fimmu.2022.1032411.s007
Language:
Unknown
Publisher:
Frontiers Media SA
Publication Date:
2022
detail.hit.zdb_id:
2606827-8
Permalink